Scpharmaceuticals Stock Performance
| SCPH Stock | USD 3.28 0.14 4.09% |
The entity has a beta of 0.3, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Scpharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Scpharmaceuticals is expected to be smaller as well. At this point, Scpharmaceuticals has a negative expected return of -0.41%. Please make sure to validate Scpharmaceuticals' skewness, as well as the relationship between the rate of daily change and price action indicator , to decide if Scpharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Scpharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in February 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Actual Historical Performance (%)
One Day Return (4.09) | Five Day Return (2.09) | Year To Date Return (8.12) | Ten Year Return (76.74) | All Time Return (76.74) |
1 | scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 | 11/06/2024 |
2 | Prothena Reports Q3 Loss, Misses Revenue Estimates | 11/12/2024 |
3 | scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update | 11/13/2024 |
4 | scPharmaceuticals Inc. Q3 2024 Earnings Call Transcript | 11/15/2024 |
5 | scPharmaceuticals Float Percentage Of Total Shares Outstanding 88.47 percent - GuruFocus.com | 11/21/2024 |
6 | Acquisition by Schaeffer Leonard D of 6124 shares of Scpharmaceuticals at 3.37 subject to Rule 16b-3 | 11/22/2024 |
7 | Disposition of 5808 shares by Schwab Andrew J. of Scpharmaceuticals at 5.02 subject to Rule 16b-3 | 11/26/2024 |
8 | Rubric Capital Management LP Boosts Stake in scPharmaceuticals Inc. - MarketBeat | 11/27/2024 |
9 | 2 Strong Buy-Rated Biotech Stocks With 303 percent To 446 percent Upside Potential - Barchart | 12/17/2024 |
10 | Disposition of 5235 shares by Rachael Nokes of Scpharmaceuticals at 3.5587 subject to Rule 16b-3 | 01/03/2025 |
11 | scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results | 01/10/2025 |
| Begin Period Cash Flow | 71.2 M |
Scpharmaceuticals |
Scpharmaceuticals Relative Risk vs. Return Landscape
If you would invest 442.00 in Scpharmaceuticals on October 20, 2024 and sell it today you would lose (114.00) from holding Scpharmaceuticals or give up 25.79% of portfolio value over 90 days. Scpharmaceuticals is currently does not generate positive expected returns and assumes 3.5949% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Scpharmaceuticals, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Scpharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Scpharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Scpharmaceuticals, and traders can use it to determine the average amount a Scpharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1154
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SCPH |
Estimated Market Risk
| 3.59 actual daily | 31 69% of assets are more volatile |
Expected Return
| -0.41 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Scpharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Scpharmaceuticals by adding Scpharmaceuticals to a well-diversified portfolio.
Scpharmaceuticals Fundamentals Growth
Scpharmaceuticals Stock prices reflect investors' perceptions of the future prospects and financial health of Scpharmaceuticals, and Scpharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Scpharmaceuticals Stock performance.
| Return On Equity | -1.67 | ||||
| Return On Asset | -0.42 | ||||
| Profit Margin | (2.65) % | ||||
| Operating Margin | (1.81) % | ||||
| Current Valuation | 132.15 M | ||||
| Shares Outstanding | 50.04 M | ||||
| Price To Book | 5.57 X | ||||
| Price To Sales | 5.42 X | ||||
| Revenue | 13.59 M | ||||
| Gross Profit | 21.11 M | ||||
| EBITDA | (46.06 M) | ||||
| Net Income | (54.81 M) | ||||
| Cash And Equivalents | 55.85 M | ||||
| Cash Per Share | 2.04 X | ||||
| Total Debt | 40.27 M | ||||
| Debt To Equity | 0.32 % | ||||
| Current Ratio | 3.72 X | ||||
| Book Value Per Share | 1.03 X | ||||
| Cash Flow From Operations | (59.24 M) | ||||
| Earnings Per Share | (1.95) X | ||||
| Market Capitalization | 164.13 M | ||||
| Total Asset | 94.48 M | ||||
| Retained Earnings | (281.35 M) | ||||
| Working Capital | 79.8 M | ||||
About Scpharmaceuticals Performance
By evaluating Scpharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Scpharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Scpharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Scpharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 973.65 | 924.97 | |
| Return On Tangible Assets | (0.52) | (0.55) | |
| Return On Capital Employed | (0.78) | (0.74) | |
| Return On Assets | (0.52) | (0.55) | |
| Return On Equity | (1.69) | (1.61) |
Things to note about Scpharmaceuticals performance evaluation
Checking the ongoing alerts about Scpharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Scpharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Scpharmaceuticals generated a negative expected return over the last 90 days | |
| Scpharmaceuticals has high historical volatility and very poor performance | |
| Scpharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 13.59 M. Net Loss for the year was (54.81 M) with profit before overhead, payroll, taxes, and interest of 21.11 M. | |
| Scpharmaceuticals currently holds about 55.85 M in cash with (59.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.04. | |
| Over 82.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results |
- Analyzing Scpharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Scpharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Scpharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Scpharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Scpharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Scpharmaceuticals' stock. These opinions can provide insight into Scpharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Scpharmaceuticals Stock analysis
When running Scpharmaceuticals' price analysis, check to measure Scpharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scpharmaceuticals is operating at the current time. Most of Scpharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Scpharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scpharmaceuticals' price. Additionally, you may evaluate how the addition of Scpharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Stocks Directory Find actively traded stocks across global markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |